BS 5839 Part 1

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Retrieved on: 
Friday, December 8, 2023
Trastuzumab, Research, Progression-free survival, RECIST, Fulvestrant, Breast cancer, Jazz Pharmaceuticals, Patient, PFS, Part, Corr, DOR, MBC, DCR, Pertuzumab, HER2, Cancer, Vall d'Hebron University Hospital, BS 5839 Part 1, Metastasis, HR, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Patients treated with the combination regimen received a median of four prior systemic regimens in the metastatic setting (range, 1-12).
  • Recommended doses of the zanidatamab plus palbociclib and fulvestrant combination therapy were determined in Part 1 of the study.
  • Patients treated with the combination regimen achieved a cORR of 35% and DCR of 91%.

NAHREP and the Hispanic Wealth Project Report on the Drivers of Hispanic Wealth

Retrieved on: 
Thursday, September 28, 2023
BS 5839 Part 1, Federal, COVID-19, HWP, Part, Urban Institute, Retirement, Federal Reserve, The Urban Institute, Growth, National Association, Education, Bottled water, Drug

MIAMI, Sept. 28, 2023 /PRNewswire-PRWeb/ -- The National Association of Hispanic Real Estate Professionals (NAHREP®) and the Hispanic Wealth Project™ (HWP) unveiled Part 1 of the annual State of Hispanic Wealth Report (SHWR) today at the L'ATTITUDE conference. The report, titled "Drivers of Wealth," provides a comprehensive assessment of the progress achieved and challenges remaining in narrowing the wealth divide between Hispanic and non-Hispanic white households. The full report, scheduled for release on November 9 at the HWP Hispanic Wealth Symposium in Washington D.C., will analyze updated household wealth data from the Federal Reserve.

Key Points: 
  • MIAMI, Sept. 28, 2023 /PRNewswire-PRWeb/ -- The National Association of Hispanic Real Estate Professionals (NAHREP®) and the Hispanic Wealth Project™ (HWP) unveiled Part 1 of the annual State of Hispanic Wealth Report (SHWR) today at the L'ATTITUDE conference .
  • The report, titled "Drivers of Wealth," provides a comprehensive assessment of the progress achieved and challenges remaining in narrowing the wealth divide between Hispanic and non-Hispanic white households.
  • The full report, scheduled for release on November 9 at the HWP Hispanic Wealth Symposium in Washington D.C., will analyze updated household wealth data from the Federal Reserve.
  • NAHREP and The Hispanic Wealth Project remain steadfast in their commitment to empowering the Hispanic community through financial education and opportunities for wealth creation.

BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

Retrieved on: 
Thursday, May 25, 2023
Yale School of Medicine, Bradycardia, Orthostatic hypotension, Dexmedetomidine, Somnolence, Schizophrenia, Xerostomia, Hypotension, Safety, Tolerability, Yale school, BS 5839 Part 1, II, Șaeș, Alignment, Incidence, PEC, Dizziness, Patient, Translational research, Psychiatry, Artificial intelligence, FDA, Therapy, Agitation, Bipolar disorder, Caregiver, DSM-IV codes, Vaccine, Pharmaceutical industry, Part

BXCL501 would represent the first-ever FDA approved therapy for at-home use in this indication, if approved.

Key Points: 
  • BXCL501 would represent the first-ever FDA approved therapy for at-home use in this indication, if approved.
  • SERENITY III is a two-part, double-blinded, placebo-controlled pivotal study designed to evaluate BXCL501 in acutely agitated adult patients with bipolar disorders or schizophrenia for at-home use.
  • Although the primary efficacy endpoint was not statistically significant at 2 hours (p=0.077), BXCL501 separated from placebo at 4 hours (p=0.049).
  • These data provide a clear path for initiating SERENITY III Part 2, to pursue approval in the at-home setting.

Pipestone Energy Corp. Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Wednesday, November 23, 2022
COVID-19, Issuer, Engineering, Geography, Chartered, Natural gas, BS 5839 Part 1, MD, News, Tax, Petroleum, GAAP, Atlas, Public expenditure, Risk management, Pipestone

In the interest of providing shareholders of Pipestone and potential investors information regarding Pipestone, this news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.

Key Points: 
  • In the interest of providing shareholders of Pipestone and potential investors information regarding Pipestone, this news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.
  • All statements other than statements of current or historical fact constitute forward-looking statements.
  • The forward-looking statements contained herein reflect management's current views, but the assessments and assumptions upon which they are based may prove to be incorrect.
  • Readers are cautioned that boe figures may be misleading, particularly if used in isolation.

XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

Retrieved on: 
Wednesday, July 13, 2022
Knowledge, Clinical trial, Unitary state, SEC, Oxipurinol, Chronic pain, Safety, TSX Venture Exchange, Uric acid, Security (finance), Diabetic nephropathy, U.S. Securities and Exchange Commission, Pharmacokinetics, Incidence, Part, News, Food, Therapy, No, Patient, CEO, Form, Xanthine oxidase, GLOBE, Coronavirus, COVID-19, Polycystic kidney disease, Diagnosis, Analysis, Population, Autosome, International, Cyst, XRX, BS 5839 Part 1, Fibrosis, Kidney disease, Part Two, Quality of life, Health, NASDAQ, Decision-making, Pharmaceutical industry, Generic drug, EU, ADPKD, Nasdaq

Part 1 of the PK Clinical Trial involved dosing under fasted conditions.

Key Points: 
  • Part 1 of the PK Clinical Trial involved dosing under fasted conditions.
  • Part 2 will measure the effect of food on pharmacokinetics and Part 3 is a multiple dose pharmacokinetics evaluation.
  • The PK Clinicial Trial is designed to permit XORTX to characterize the safety and relative bioavailability of the XRx-008 program formulations.
  • Knowledge gained during the conduct of this PK Clinical Trial is now providing critical guidance regarding the oral dosing for our planned phase 3 registration trial in ADPKD.

Pipestone Energy Corp. Announces Inaugural Normal Course Issuer Bid

Retrieved on: 
Monday, November 22, 2021
Chartered, Public expenditure, News, Geography, Indian stock exchange, Forward-looking statement, Income, MD, COVID-19, Atlas, Tax, GAAP, Petroleum, BS 5839 Part 1, IFRS, Engineering, Natural gas, Risk management

In the interest of providing shareholders of Pipestone and potential investors information regarding Pipestone, this news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.

Key Points: 
  • In the interest of providing shareholders of Pipestone and potential investors information regarding Pipestone, this news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.
  • All statements other than statements of current or historical fact constitute forward-looking statements.
  • The forward-looking statements contained herein reflect management's current views, but the assessments and assumptions upon which they are based may prove to be incorrect.
  • Readers are cautioned that boe figures may be misleading, particularly if used in isolation.

Pipestone Energy Corp. Reports Record Third Quarter 2021 Results and Provides an Operations Update

Retrieved on: 
Wednesday, November 10, 2021
ROCE, Efficiency, Tax, G&A, Contract, News, National instrument, MD, Engineering, Petroleum, Transport, Income, Depreciation, IFRS, COVID-19, Geography, DCE, Forward-looking statement, Natural gas, Chartered, Public expenditure, Montney, British Columbia, EBITDA, Propane, Risk management, Company, EBIT, Disclosure, DUCS, Atlas, Hydrocarbon, GAAP, Nature, ROU, Time, BS 5839 Part 1, Bank, Life insurance, Security (finance), Bookkeeping, Oil

Pipestone uses adjusted funds flow from operations (cash from operating activities before changes in non-cash working capital and decommissioning provision costs incurred), a measure that is not defined under IFRS.

Key Points: 
  • Pipestone uses adjusted funds flow from operations (cash from operating activities before changes in non-cash working capital and decommissioning provision costs incurred), a measure that is not defined under IFRS.
  • Net debt is considered to be a useful measure in assisting management and investors to evaluate Pipestones financial strength.
  • The purpose of this financial outlook is to provide readers with disclosure of the companys reasonable expectations of our anticipate results.
  • Actual results will differ from those realized during an initial production period or short-term test period, and the difference may be material.

Pipestone Energy Corp. Announces Appointment of New Director, Distribution of Common Shares By Its Largest Shareholder Canadian Non-Operated Resources L.P. and Updated Investor Rights Arrangements

Retrieved on: 
Friday, September 24, 2021
News, Tax, Public expenditure, Water, Petroleum, BS 5839 Part 1, Income, Atlas, Engineering, MD, Natural gas, Method, Public policy, Growth, Chartered, Geography, SEDAR, Share repurchase, GAAP, COVID-19, IFRS, Forward-looking statement, Risk management, Bank, Life insurance

This news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.

Key Points: 
  • This news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.
  • All statements other than statements of current or historical fact constitute forward-looking statements.
  • The forward-looking statements contained herein reflect management's current views, but the assessments and assumptions upon which they are based may prove to be incorrect.
  • This press release includes references to financial measures commonly used in the oil and natural gas industry.

Pipestone Energy Corp. Reports Record Second Quarter 2021 Results and Provides an Operations Update

Retrieved on: 
Wednesday, August 11, 2021
Risk management, Income, News, Nature, Depreciation, Company, Hydrocarbon, G&A, Public expenditure, Atlas, Efficiency, BS 5839 Part 1, Contract, Montney, British Columbia, ROU, Chartered, Time, Forward-looking statement, Petroleum, Geography, MD, COVID-19, Engineering, GAAP, Natural gas, IFRS, Disclosure, Transport, Tax, ROCE, Propane, Line of credit, EBITDA, National instrument, EBIT, Bank, Life insurance, Security (finance), Bookkeeping, Oil

Pipestone Energy uses adjusted funds flow from operations (cash from operating activities before changes in non-cash working capital and decommissioning provision costs incurred), a measure that is not defined under IFRS.

Key Points: 
  • Pipestone Energy uses adjusted funds flow from operations (cash from operating activities before changes in non-cash working capital and decommissioning provision costs incurred), a measure that is not defined under IFRS.
  • Net debt is considered to be a useful measure in assisting management and investors to evaluate Pipestone Energys financial strength.
  • The purpose of this financial outlook is to provide readers with disclosure of the companys reasonable expectations of our anticipate results.
  • Actual results will differ from those realized during an initial production period or short-term test period, and the difference may be material.